D. J. Silver

Connexin 43 drives glioblastoma cancer stem cell phenotypes through a WNK lysine-deficient protein kinase 1-c-MYC signaling axis

This study shows that Cx43 promotes glioblastoma cancer stem cell survival and self-renewal via a WNK1-c-MYC signaling pathway.

Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition

This study shows that spermidine, a metabolite from glioblastoma cells, suppresses CD8+ T cell function, promoting tumor growth and poor patient outcomes.

Sex-specific T cell exhaustion drives differential immune responses in glioblastoma

This study shows male T cells are more exhausted in glioblastoma, leading to worse outcomes and better response to anti-PD1 treatment compared to females.

Tumor cell-intrinsic HFE drives glioblastoma growth

This study shows that HFE promotes glioblastoma growth by regulating iron homeostasis and oxidative stress, with HFE loss inducing apoptosis and extending survival.

SerpinB3 drives cancer stem cell survival in glioblastoma

This study identifies SerpinB3 as a key driver of glioblastoma cancer stem cell survival and shows that targeting it enhances radiation therapy efficacy in pre-clinical models.

WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma

This study identifies WDR5 as an essential epigenetic regulator in therapy-resistant glioblastoma cancer stem cells and shows that WDR5 inhibitors disrupt CSC maintenance and tumor growth.

Pretreatment with LCK Inhibitors Chemosensitizes Cisplatin-Resistant Endometrioid Ovarian Tumors

This study shows that pretreatment with LCK inhibitors makes cisplatin-resistant endometrioid ovarian tumors more sensitive to cisplatin, improving cell viability and tumor growth inhibition.

Cancer Stem Cell Enrichment and Metabolic Substrate Adaptability are Driven by Hydrogen Sulfide Suppression in Glioblastoma

A high-fat diet accelerates glioblastoma by inhibiting hydrogen sulfide production, leading to cancer stem cell enrichment and reduced treatment response.

Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner

This study identifies sex-specific roles of MDSC subsets in glioblastoma, showing mMDSCs drive growth in males and gMDSCs in females, with potential therapeutic targets.

Membrane-Bound O-Acyltransferase 7 (MBOAT7) is a Key Regulator of Glycolysis in Clear Cell Renal Carcinoma.

This study shows MBOAT7 regulates glycolysis in ccRCC by reducing glycolytic gene expression, intermediates, and respiration, and improving survival in xenograft models.

Cholangiocarcinoma presents a distinct myeloid-derived suppressor cell signature compared to other hepatobiliary cancers

The paper identifies a distinct myeloid-derived suppressor cell (MDSC) signature in cholangiocarcinoma (CCA) compared to other hepatobiliary cancers, linking MDSC levels to disease outcomes and potential therapeutic targets.

JAM-A functions as a female microglial tumor suppressor in glioblastoma

This study shows that JAM-A deficiency in female mice increases microglia activation and GBM growth, revealing a sex-specific role for JAM-A in the tumor microenvironment.

Identifying conserved molecular targets required for cell migration of glioblastoma cancer stem cells

This study identifies Rap1a as a conserved regulator of glioblastoma cancer stem cell migration using a combination of Drosophila and human models.

MBOAT7-Driven Phosphatidylinositol Remodeling Promotes the Progression of Clear Cell Renal Cell Carcinoma.

This study identifies MBOAT7-driven phosphatidylinositol remodeling as a driver of clear cell renal cell carcinoma progression and highlights MBOAT7 as a potential therapeutic target.

Asymmetric Division Promotes Therapeutic Resistance In Glioblastoma Stem Cells

The paper shows that asymmetric division in glioblastoma stem cells generates daughter cells with enhanced therapeutic resistance and co-inherited growth factor receptors.

ADAMDEC1 maintains a novel growth factor signaling loop in cancer stem cells

This study identifies a novel signaling loop involving ADAMDEC1 and FGF2/FGFR1 that maintains glioblastoma cancer stem cells and shows targeting this loop reduces tumor growth.

Development of a Cx46 targeting strategy for cancer stem cells

This study identifies clofazimine as a Cx46 inhibitor that targets glioblastoma cancer stem cells by disrupting gap junction communication, enhancing the efficacy of temozolomide.